SCHEMBL6812993

SCHEMBL6812993

CS(=O)(=O)OCCC1OCCc2cc(Br)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 7/20 0.36
DRD2 P14416 7/20 0.36
HTR2A P28223 5/20 0.36
DRD4 P21917 4/20 0.36
HTR1A P08908 3/20 0.36
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
HTR1B P28222 2/20 0.34
THRB P10828 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA13 Q8N1Q1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5088651 1.00 HTR1D (0.36) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6811873 0.85 HTR6 (0.39) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL5090703 0.82 HTR1D (0.41) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL5088740 0.82 HTR1D (0.53) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6808402 0.82 HTR1D (0.53) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL5138899 0.82 DRD2 (0.47) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6808621 0.81 HTR2C (0.39) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6812183 0.81 HTT (0.38) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6811442 0.80 HTR1D (0.42) HTR1DDRD2HTR2ADRD4HTR1A
SCHEMBL6917704 0.80 HTT (0.41) DRD2DRD4MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040122001-A1 Pharmaceutical compounds ELI LILLY AND COMPANY 2004-06-24 US disclosed
US-6133446-A Heterocyclic compounds for the treatment of CNS and cardiovascular disorders PHARMACIA & UPJOHN COMPANY (US) 2000-10-17 US disclosed
EP-0737189-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS UPJOHN CO (US) 1999-07-28 EP disclosed
US-5877317-A Heterocyclic compounds for the treatment of CNS and cardiovascular disorders PHARMACIA & UPJOHN COMPANY (US) 1999-03-02 US disclosed
EP-0737189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS PHARMACIA & UPJOHN COMPANY (US) 1996-10-16 EP disclosed
WO-1995018118-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS THE UPJOHN COMPANY (US) 1995-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122001-A1 Pharmaceutical compounds CYP2D6, LPXN, CYP1B1 HTR1D 124/4885DRD2 1606/4885HTR2A 2038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.